Back to top
more

SAB Biotherapeutics (SABS)

(Delayed Data from NSDQ)

$4.19 USD

4.19
2,678

-0.06 (-1.41%)

Updated Apr 29, 2024 03:31 PM ET

After-Market: $4.25 +0.06 (1.43%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SABS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

SAB Biotherapeutics, Inc. [SABS]

Reports for Purchase

Showing records 1 - 17 ( 17 total )

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 1

01/08/2024

Company Report

Pages: 7

Updating Model After Reverse Stock Split

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 2

11/29/2023

Daily Note

Pages: 3

Dosing Commences in First-in-Man Phase 1 Study of SAB-142

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 3

11/14/2023

Company Report

Pages: 8

3Q23 Results; Phase 1 Trial of SAB-142 in Healthy Volunteers Planned to Start This Quarter; Lowering PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 4

10/19/2023

Daily Note

Pages: 3

SAB Receives Approval to Conduct Phase 1 Study of SAB-142 in Australia

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 5

10/06/2023

Company Report

Pages: 7

Model Update Following Private Placement

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 6

08/21/2023

Company Report

Pages: 8

2Q23 Results; SAB-142 Projected to Enter the Clinic in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 7

06/21/2023

Daily Note

Pages: 3

Positive Results From IND-Enabling GLP Toxicology Study For SAB-142

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 8

06/16/2023

Company Report

Pages: 8

Research and Development Day Recap; Focus Now on SAB-142 Program in Type 1 Diabetes

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 9

05/17/2023

Company Report

Pages: 8

1Q23 Results; Phase 2b Study of SAB-176 Could Start by YE23; IND Filings for SAB-195 and SAB-142 Expected 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 10

05/12/2023

Daily Note

Pages: 4

SAB-183 Non-Clinical Data Published in the Medical Journal Antibodies

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 11

04/26/2023

Daily Note

Pages: 3

Compelling Phase 3 Top-Line Results of SAB-185 in COVID-19 Patients Give Confidence in the Polyclonal Antibody Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 12

04/18/2023

Company Report

Pages: 8

FY22 Financials; SAB-176 Receives Breakthrough Therapy Designation For Influenza Treatment

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 13

04/13/2023

Daily Note

Pages: 3

SAB Biotherapeutics Announces FDA Fast Track Designation For SAB-176 Influenza Candidate

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 14

04/03/2023

Daily Note

Pages: 3

Full-Year 2022 Company Update Issued

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 15

01/18/2023

Company Report

Pages: 7

SAB Receives an Additional $8.2 Million From Department of Defense Contract Closeout

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 16

01/10/2023

Daily Note

Pages: 3

Successful IND-Enabling GLP Toxicology Study For SAB-142

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: SAB Biotherapeutics, Inc.

Industry: Unclassified

Record: 17

11/29/2022

Company Report

Pages: 30

Holy Cow! An Innovative Way to Develop Polycolonal Antibodies; Initiate With Buy Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 35.00

Research Provided by a Third Party